Article | December 15, 2020

Cell And Gene Therapies Require Highly Specialized Formulation And Manufacturing Capabilities

By Dr. Maaike Everts, Technical Marketing Leader, Parenteral Drug Delivery, Evonik

Evonik-Cell Article #12 Dec LSC NLI_2015_11

Recent improvements in our understanding of the human genome, together with advanced DNA editing and analytical tools, position the cell and gene therapy market for explosive growth over the coming decade. However, these technologies have significant formulation development, cGMP manufacturing and aseptic filling challenges, which must all be overcome before this potential can be fully commercialized. The engagement of a CDMO partner with a broad portfolio of delivery technologies, a strong formulation track record and manufacturing flexibility is the preferred pathway for success within this highly specialized area.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: